Search results for: Genetic
Filter search results
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
…Christodoulou, J., Leventer, R. J., Lockhart, P. J., Stark, Z., Boughtwood, T., & Goranitis, I. (2020). Parental health spillover effects of paediatric rare genetic conditions. Quality of Life Research, 29(9),…
The challenges and economics of drug development in 2022
1 July 2013
…be radically transformed as “precision” medicine plugs into the specific genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics. 2. Innovation will be…
Infants at Risk
1 July 1964
…Birth requires more rapid adaptation to new circumstances than any other event in an individual’s life. A baby’s survival and healthy growth depend not only on his genetic equipment, but…
Finance of Medical Research
7 January 1964
…to the chest, heart and brain and in to the extremes of life; general medicine is concerned with molecular biology, auto-immune disease and human genetics; psychological medicine now offers some…
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…Hughes (Avalere Health LLC). Panellists: Adrian Towse (OHE), Sachin Kamal-Bahl (Pfizer), Alastair Kent (Genetic Alliance UK). Maintaining patient focus in healthcare decision-making is a universally-accepted approach to ensuring positive outcomes….
Economic Aspects of Non-Hodgkin’s Lymphoma
1 July 1998
…for NHL have been proffered and some links established (for example, the existence of infectious agents such as HIV, and genetic susceptibility), there is still much uncertainty surrounding all the…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…this publication. 1. Health care will be radically transformed as “precision” medicines plug into the specific genetic makeup of both patients and diseases, paired with increasingly powerful and convenient diagnostics….
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…managers. Germany’s financial institutions and its laws governing genetic engineering, intellectual property, and employment created longstanding institutional obstacles to the development of high-technology industries and markets for venture capital and…
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In…